Hematologic malignancy
Conditions
Interventions
Experimental group:Avatrombopag Maleate
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years; 2. Patients with secondary thrombocytopenia (drug, anti-infection and other factors) 30 days after allogeneic transplantation (PLT<=30x10^9/L); 3. Life expectancy greater than 3 months; 4. ECOG score 0-2; 5. Consent to receive post-transplant treatment with avatropapa, and signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating subjects; 2. Chronic active hepatitis B and C; 3. Subjects with thrombotic microangiopathy; 4. Severe heart disease, severe lung disease, diabetes and severe metabolic diseases; 5. Active thromboembolism requires anticoagulation; 6. Subjects will participate in another clinical study using any exploratory drugs or devices within 30 days prior to their baseline visit; Participation in observational studies is allowed; 7. The investigator believes that the concomitant history may affect the safety of the subjects in completing the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet; | — |
Countries
China
Contacts
Public ContactLi Xin/Cheng Qian
The Third Xiangya Hospital of Central South University
Outcome results
None listed